BRPI0915928B8 - anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos - Google Patents

anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos

Info

Publication number
BRPI0915928B8
BRPI0915928B8 BRPI0915928A BRPI0915928A BRPI0915928B8 BR PI0915928 B8 BRPI0915928 B8 BR PI0915928B8 BR PI0915928 A BRPI0915928 A BR PI0915928A BR PI0915928 A BRPI0915928 A BR PI0915928A BR PI0915928 B8 BRPI0915928 B8 BR PI0915928B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
functional protein
isolated antibody
antibodies
same
Prior art date
Application number
BRPI0915928A
Other languages
English (en)
Inventor
Heusser Christoph
Schaadt Eveline
Neugebauer Julia
Woisetschlaeger Maximilian
Urlinger Stefanie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915928(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0915928A2 publication Critical patent/BRPI0915928A2/pt
Publication of BRPI0915928B1 publication Critical patent/BRPI0915928B1/pt
Publication of BRPI0915928B8 publication Critical patent/BRPI0915928B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpo isolado ou proteína funcional, seu processo de produção, composição farmacêutica, ácido nucleico isolado, vetor de expressão ou clonagem, e célula hospedeira. a presente invenção se refere aos anticorpos que especificamente se ligam ao receptor de baff (baffr). a invenção mais especificamente refere-se aos anticorpos específicos que são antagonistas de baffr com atividade de depleção de célula b in vivo e composições de métodos de uso para os referidos anticorpos para tratar distúrbios patológicos que possam ser tratados exterminando-se ou depauperando-se as células b, tal como lúpus eritematoso sistêmico ou artrite reumatoide ou outras doenças imunes ou linfomas, leucemias e mielomas.
BRPI0915928A 2008-07-17 2009-07-15 anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos BRPI0915928B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08160671.7 2008-07-17
EP08160671 2008-07-17
EP09160326.6 2009-05-15
EP09160326 2009-05-15
PCT/EP2009/059030 WO2010007082A1 (en) 2008-07-17 2009-07-15 Compositions and methods of use for therapeutic antibodies

Publications (3)

Publication Number Publication Date
BRPI0915928A2 BRPI0915928A2 (pt) 2015-11-03
BRPI0915928B1 BRPI0915928B1 (pt) 2020-10-20
BRPI0915928B8 true BRPI0915928B8 (pt) 2021-05-25

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915928A BRPI0915928B8 (pt) 2008-07-17 2009-07-15 anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos

Country Status (40)

Country Link
US (3) US8106163B2 (pt)
EP (1) EP2315780B8 (pt)
JP (2) JP5767109B2 (pt)
KR (2) KR101314369B1 (pt)
CN (1) CN102119174B (pt)
AR (1) AR072749A1 (pt)
AU (1) AU2009272771B2 (pt)
BR (1) BRPI0915928B8 (pt)
CA (1) CA2730063C (pt)
CL (1) CL2011000086A1 (pt)
CR (1) CR11863A (pt)
CU (1) CU23878B1 (pt)
CY (1) CY1116800T1 (pt)
DK (1) DK2315780T3 (pt)
DO (1) DOP2011000016A (pt)
EA (1) EA024492B1 (pt)
EC (1) ECSP11010761A (pt)
ES (1) ES2547270T3 (pt)
GE (1) GEP20146129B (pt)
HR (1) HRP20151227T1 (pt)
HU (1) HUE025778T2 (pt)
IL (1) IL210485A (pt)
JO (1) JO3149B1 (pt)
MA (1) MA32481B1 (pt)
MX (1) MX2011000616A (pt)
MY (1) MY158980A (pt)
NI (1) NI201100017A (pt)
NZ (1) NZ590057A (pt)
PE (1) PE20110563A1 (pt)
PL (1) PL2315780T3 (pt)
PT (1) PT2315780E (pt)
RS (1) RS54299B1 (pt)
SG (1) SG193805A1 (pt)
SI (1) SI2315780T1 (pt)
SM (1) SMP201100010B (pt)
SV (1) SV2011003807A (pt)
TW (1) TWI508742B (pt)
UY (1) UY31987A (pt)
WO (1) WO2010007082A1 (pt)
ZA (1) ZA201008952B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
US9321842B2 (en) * 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
PL3413894T3 (pl) 2016-02-10 2020-10-05 Novartis Ag Zastosowanie inhibitorów aktywności lub czynności PI3K do leczenia pierwotnego zespołu Sjögrena
CN116041514A (zh) * 2016-06-06 2023-05-02 希望之城 Baff-r抗体及其用途
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
CN110662768B (zh) * 2017-05-24 2024-01-30 Als治疗发展学会 治疗性抗cd40配体抗体
IL271194B2 (en) * 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
PL3823990T3 (pl) * 2018-07-20 2026-04-20 TeneoTwo, Inc. Przeciwciała łańcucha ciężkiego wiążące się z cd19
JPWO2020202839A1 (pt) * 2019-03-29 2020-10-08
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
JP2023501781A (ja) 2019-11-06 2023-01-19 ノバルティス アーゲー シェーグレン症候群の処置
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
US20230340136A1 (en) * 2020-08-04 2023-10-26 Novartis Ag Treatment of cll
IL300086A (en) 2020-08-04 2023-03-01 Novartis Ag Treatment of B-cell malignancies
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
US20250215081A1 (en) * 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
US20240228644A1 (en) * 2021-05-04 2024-07-11 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
JP2024517796A (ja) * 2021-05-04 2024-04-23 ノバルティス アーゲー 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP2024537772A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂａｆｆ－ｒを標的化する抗体及びその使用
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体
WO2025058962A1 (en) * 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en) 2023-12-19 2025-06-26 Basf Se Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75049C2 (uk) * 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
BRPI0518994A2 (pt) * 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
SG193805A1 (en) 2013-10-30
EP2315780B1 (en) 2015-08-19
DK2315780T3 (en) 2015-10-19
EP2315780B8 (en) 2015-09-23
EA024492B1 (ru) 2016-09-30
IL210485A (en) 2015-03-31
PT2315780E (pt) 2015-11-30
CN102119174A (zh) 2011-07-06
KR101314369B1 (ko) 2013-10-10
US20120195913A1 (en) 2012-08-02
ES2547270T3 (es) 2015-10-05
MA32481B1 (fr) 2011-07-03
UY31987A (es) 2010-02-26
CN102119174B (zh) 2015-01-21
JP2011527896A (ja) 2011-11-10
AR072749A1 (es) 2010-09-15
NI201100017A (es) 2012-08-17
CR11863A (es) 2011-02-11
DOP2011000016A (es) 2011-02-15
JP6077587B2 (ja) 2017-02-08
JO3149B1 (ar) 2017-09-20
WO2010007082A1 (en) 2010-01-21
CU23878B1 (es) 2013-04-19
CA2730063C (en) 2017-04-18
JP5767109B2 (ja) 2015-08-19
US9382326B2 (en) 2016-07-05
HUE025778T2 (en) 2016-05-30
KR101545795B1 (ko) 2015-08-19
ZA201008952B (en) 2012-01-25
AU2009272771B2 (en) 2012-09-20
EA201100191A1 (ru) 2011-08-30
SMP201100010B (it) 2011-09-09
HRP20151227T1 (hr) 2015-12-18
KR20110020914A (ko) 2011-03-03
US8106163B2 (en) 2012-01-31
AU2009272771A1 (en) 2010-01-21
SI2315780T1 (sl) 2015-11-30
JP2015133983A (ja) 2015-07-27
PE20110563A1 (es) 2011-08-29
CL2011000086A1 (es) 2011-07-01
TWI508742B (zh) 2015-11-21
RS54299B1 (sr) 2016-02-29
GEP20146129B (en) 2014-08-11
CU20110013A7 (es) 2012-06-21
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
TW201006493A (en) 2010-02-16
US9340620B2 (en) 2016-05-17
PL2315780T3 (pl) 2016-01-29
US20100021452A1 (en) 2010-01-28
SV2011003807A (es) 2011-03-23
CA2730063A1 (en) 2010-01-21
NZ590057A (en) 2012-08-31
ECSP11010761A (es) 2011-02-28
MY158980A (en) 2016-11-30
MX2011000616A (es) 2011-02-24
CY1116800T1 (el) 2017-03-15
KR20130098432A (ko) 2013-09-04
BRPI0915928A2 (pt) 2015-11-03
IL210485A0 (en) 2011-03-31
BRPI0915928B1 (pt) 2020-10-20
HK1150839A1 (en) 2012-01-13
EP2315780A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
BRPI0915928B8 (pt) anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos
BR112015017338A8 (pt) anticorpo ou proteína isolada, sua composição farmacêutica, seu uso, seu processo de produção, molécula de ácido nucleico isolada, vetor de clonagem ou de expressão e célula hospedeira
MX2025003310A (es) Integracion dirigida de acidos nucleicos
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
JOP20200102A1 (ar) جزيئات ترابط إنتجرين واستخداماتها
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
BR112019006388A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
BR112019006384A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
CL2013003296A1 (es) Uso de un agonista del receptor 1 del factor de crecimiento anti-fibroblastos (fgfr1) para tratar enfermedades tales como sindrome de ovario poliquístico (pcos), sindrome metabólico, obesidad, estrato hepatitis no alcohólica (nash), entre otras; anticuerpo que se une con fgfr1; acido nucleico aislado; célula huesped.
BR112012007860A2 (pt) "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"
EA201790968A1 (ru) Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
WO2014176531A3 (en) Co-solvent to produce reactive intermediates from biomass
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
EA201370076A1 (ru) Иммуноглобулины-переносчики и их применение
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
BR112016013400A2 (pt) métodos para modificar um genoma e para produzir um camundongo
BR112012015255A2 (pt) "anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante"
BR112016003339A2 (pt) composição de enzima, e, processo de produção de um produto de fermentação a partir de material contendo amido
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
BR112015009774A2 (pt) polipeptídeos citocromo p450 e citocromo p450 redutase, codificando moléculas de ácido nucléicos e usos das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF